4.7 Review

The VHL tumor suppressor and HIF: insights from genetic studies in mice

期刊

CELL DEATH AND DIFFERENTIATION
卷 15, 期 4, 页码 650-659

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/sj.cdd.4402313

关键词

von Hippel-Lindau (VHL) tumor suppressor; hypoxia-inducible factor (HIF); conditional knockout mice; renal cell cancer; hemangiomas; vascular tumors

资金

  1. NCI NIH HHS [R01 CA100787] Funding Source: Medline
  2. NIDDK NIH HHS [K08 DK002668, R21 DK072037, R21 DK073467] Funding Source: Medline
  3. NATIONAL CANCER INSTITUTE [R01CA100787] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002668, R21DK072037, R21DK073467] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The von Hippel-Lindau tumor suppressor gene product, pVHL, functions as the substrate recognition component of an E3-ubiquitin ligase, which targets the oxygen-sensitive alpha-subunit of hypoxia-inducible factor (HIF) for rapid proteasomal degradation under normoxic conditions and as such plays a central role in molecular oxygen sensing. Mutations in pVHL can be found in familial and sporadic clear cell carcinomas of the kidney, hemangioblastomas of the retina and central nervous system, and pheochromocytomas, underscoring its gatekeeper function in the pathogenesis of these tumors. Tissue-specific gene targeting of VHL in mice has demonstrated that efficient execution of pVHL-mediated HIF proteolysis under normoxia is fundamentally important for survival, proliferation, differentiation and normal physiology of many cell types, and has provided novel insights into the biological function of individual HIF transcription factors. In this review, we discuss the role of HIF in the development of the VHL phenotype.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据